CCL26

Across TCGA pan-cancer cohorts, CCL26 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL26 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCL26 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL26 expression acts as an unfavorable survival marker.

BLCA, UCEC, and COAD are the cancer types where CCL26 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.149	0.710	<.001	36	view →
UCEC	OS	Median	II,III,IV	0.231	0.768	.010	24	view →
COAD	DFS	Median	II,III,IV	0.141	0.683	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL26–BLCA (OS)

Open the BLCA breakdown →